Defunct Company
Total Trials
9
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,080
NCT02648672
BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Dec 31, 2015
Completion: Jul 31, 2016
NCT02840279
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
Start: Jun 30, 2016
Completion: Dec 31, 2016
NCT03030105
Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers
Start: Jan 31, 2017
Completion: Jun 30, 2017
NCT03569631
A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome
Phase: Phase 2
Start: Jul 9, 2018
Completion: Jul 31, 2020
NCT03817684
Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects
Start: Apr 30, 2019
Completion: Feb 4, 2020
NCT04044781
A Phase 1, Open-Label, PET Study of T2310 & BPN14770
Start: Jan 10, 2020
Completion: May 30, 2020
NCT05163808
A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome
Phase: Phase 2/3
Start: Mar 29, 2022
Completion: Dec 31, 2025
NCT05358886
A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome
Phase: Phase 3
Start: Nov 1, 2022
Completion: Jul 18, 2025
NCT05367960
An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome
Completion: Dec 31, 2027